Embla Medical hf: Conference call details for Q4/FY 2025

Embla Medical (Nasdaq Copenhagen: EMBLA) will publish its Q4/FY2025 report on 3 February 2026 at 07:00 CET and host a conference call the same day at 09:00 CET / 07:00 GMT / 03:00 EST led by CEO Sveinn Solvason and CFO G. Arna Sveinsdottir; slides and a webcast will be available on the company's investor site. The announcement sets out a detailed 2026 investor-events calendar including multiple roadshows in Europe and the US, but provides no financial results, figures or guidance in this notice.

Analysis

MARKET STRUCTURE: The Q4/FY2025 report and follow-up roadshow (Feb 3–6) are a concentrated catalyst for EMBLA (Nasdaq Copenhagen: EMBLA); beneficiaries include Embla itself, its clinic network and suppliers of O&P components if guidance is upgraded, while distributors reliant on low-margin commoditized braces could be pressured. Expect a 5–20% intraday move around the print depending on revenue/gross-margin beat or miss; pricing power is driven by clinic roll‑outs and recurring patient-care revenue, so material upward share reallocation requires >15% organic revenue growth or clear M&A synergies. Cross-asset: a strong beat could tighten small-cap Nordic healthcare credit spreads and lift SEK/DKK‑USD‑correlated flows; a miss would widen small-cap spreads and raise local equity volatility, but FX and commodity impacts should be limited.

Key Decisions for Investors

• Establish a tactical 2–3% long position in EMBLA (EMBLA) ahead of the Feb 3 release, funded from small-cap healthcare shorts; if FY25 revenue growth >15% YoY and EBITDA margin expands >300bp, scale to 5% within 3 trading days.
• If EMBLA misses revenue or cuts guidance by >10% relative to consensus, liquidate the position immediately and consider a 1–2% short for 1–3 months targeting a 15–35% downside driven by re‑rating risk and potential equity raise.
• Implement an options hedge if available: buy a Feb 1–2 week call spread (buy ATM, sell 10–15% OTM) sized to 50% of equity exposure to capture upside >10% while limiting premia; alternatively, sell a backspread (ratio call) only if implied vol >40% to monetize high IV.
• Run a pair trade: long EMBLA (2%) / short XHE (SPDR S&P Healthcare Equipment ETF) (0.8% notional) for 1–3 months to capture idiosyncratic upside while hedging sector beta; rebalance after roadshow feedback by Feb 10 based on management tone and clinic KPIs.